Eiger BioPharmaceuticals, Inc. (EIGR) Can’t Be More Risky. The Stock Formed a Bearish Multiple Bottom Chart Pattern

June 12, 2018 - By Rene Maslow

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Logo

The stock of Eiger BioPharmaceuticals, Inc. (EIGR) shows a multiple bottoms pattern with $13.97 target or 5.00 % below today’s $14.70 share price. The 6 months chart pattern indicates high risk for the $201.92 million company. It was reported on Jun, 12 by Finviz.com. If the $13.97 price target is reached, the company will be worth $10.10 million less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock increased 0.68% or $0.1 during the last trading session, reaching $14.7. About 144,901 shares traded. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has risen 88.41% since June 12, 2017 and is uptrending. It has outperformed by 75.84% the S&P500.

Analysts await Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to report earnings on August, 13. They expect $-0.82 earnings per share, up 38.35 % or $0.51 from last year’s $-1.33 per share. After $-0.84 actual earnings per share reported by Eiger BioPharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -2.38 % EPS growth.

More recent Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) news were published by: Seekingalpha.com which released: “Eiger Bio -5% with $40M offering said to come at $12.50/share” on May 23, 2018. Also Streetinsider.com published the news titled: “Eiger BioPharmaceuticals (EIGR) Prices 3.2M Common Stock Offering at $12.50/Share” on May 24, 2018. Streetinsider.com‘s news article titled: “After-Hours Stock Movers 05/23: (BW) (WSM) (SMRT) Higher; (LB) (NTAP) (EIGR) Lower (more…)” with publication date: May 23, 2018 was also an interesting one.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. The company has market cap of $201.92 million. The Company’s product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. It currently has negative earnings.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: